0001493152-26-020424
SEC filingCelularity reported $26.6M in revenue for FY2025, with gross profit of $6.5M and a net loss of $91.7M, reflecting sustained operational losses and accelerating cash burn amid payer uncertainty and provider inventory caution.
Revenue for FY2025 totaled $26.6 million. This reflects continued commercial activity across Celularity’s product portfolio and its biomaterial contract manufacturing and development services, which enable scalable production across both early-stage and commercial volumes. However, the overall revenue environment was constrained by external dynamics: as noted in Management’s Discussion, providers and distributors adopted a more cautious approach to inventory and utilization—including deferring purchases or limiting order volumes—pending greater clarity on coverage parameters. This dynamic directly impacted demand realization and contributed to lower top-line performance.
Celularity’s long-term strategy centers on modulating regenerative processes by increasing the number and quality of stem cells. However, near-term financial realities necessitate urgent capital stewardship. The FY2025 results underscore that current operations are not self-sustaining, requiring strategic reallocation—including divestitures and liquidity measures—to fund the advancement of its core cell therapy pipeline.